170 related articles for article (PubMed ID: 15526708)
1. The anti-platelet approach targeting the fibrinogen ligand of the GPIIB/IIIa receptor.
Tsikaris V
J Pept Sci; 2004 Oct; 10(10):589-602. PubMed ID: 15526708
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of fibrinogen binding and surface recruitment of GpIIb/IIIa as dose-dependent effects of the RGD-mimetic MK-852.
Wittig K; Rothe G; Schmitz G
Thromb Haemost; 1998 Mar; 79(3):625-30. PubMed ID: 9531053
[TBL] [Abstract][Full Text] [Related]
3. The interaction of disagregin with the platelet fibrinogen receptor, glycoprotein IIb-IIIa.
Karczewski J; Connolly TM
Biochem Biophys Res Commun; 1997 Dec; 241(3):744-8. PubMed ID: 9434779
[TBL] [Abstract][Full Text] [Related]
4. GPIIb/IIIa inhibitors: from bench to bedside and back to bench again.
Armstrong PC; Peter K
Thromb Haemost; 2012 May; 107(5):808-14. PubMed ID: 22370973
[TBL] [Abstract][Full Text] [Related]
5. MK-383 (tirofiban) induces a GPIIb/IIIa receptor conformation which differs from the resting and activated receptor.
Barlage S; Wimmer A; Pfeiffer A; Rothe G; Schmitz G
Platelets; 2002 May; 13(3):133-40. PubMed ID: 12180495
[TBL] [Abstract][Full Text] [Related]
6. Low-density lipoprotein specifically binds glycoprotein IIb/IIIa: a flow cytometric method for ligand-receptor interaction.
Tetik S; Uras F; Ekşioğlu-Demiralp E; Turay Yardimci K
Clin Appl Thromb Hemost; 2008 Apr; 14(2):210-9. PubMed ID: 18160616
[TBL] [Abstract][Full Text] [Related]
7. Platelet GPIIb/IIIa antagonist, XV459, in heparin-induced thrombocytopenia.
Mousa SA; Ahmad S
Am J Hematol; 2007 Apr; 82(4):276-82. PubMed ID: 17039513
[TBL] [Abstract][Full Text] [Related]
8. Formation of viscoelastic protein layers on polymeric surfaces relevant to platelet adhesion.
Weber N; Wendel HP; Kohn J
J Biomed Mater Res A; 2005 Mar; 72(4):420-7. PubMed ID: 15678483
[TBL] [Abstract][Full Text] [Related]
9. Expression of ligand-induced binding sites on glycoprotein IIb/IIIa complexes and the effect of various inhibitors.
Jennings LK; White MM
Am Heart J; 1998 May; 135(5 Pt 2 Su):S179-83. PubMed ID: 9588397
[TBL] [Abstract][Full Text] [Related]
10. Use of conformationally restricted benzamidines as arginine surrogates in the design of platelet GPIIb-IIIa receptor antagonists.
Sall DJ; Arfsten AE; Bastian JA; Denney ML; Harms CS; McCowan JR; Morin JM; Rose JW; Scarborough RM; Smyth MS; Um SL; Utterback BG; Vasileff RT; Wikel JH; Wyss VL; Jakubowski JA
J Med Chem; 1997 Aug; 40(18):2843-57. PubMed ID: 9288166
[TBL] [Abstract][Full Text] [Related]
11. Fibrinogen receptor (GPIIb-IIIa) antagonists derived from 5,6-bicyclic templates. Amidinoindoles, amidinoindazoles, and amidinobenzofurans containing the N-alpha-sulfonamide carboxylic acid function as potent platelet aggregation inhibitors.
Su T; Naughton MA; Smyth MS; Rose JW; Arfsten AE; McCowan JR; Jakubowski JA; Wyss VL; Ruterbories KJ; Sall DJ; Scarborough RM
J Med Chem; 1997 Dec; 40(26):4308-18. PubMed ID: 9435900
[TBL] [Abstract][Full Text] [Related]
12. Prevention of platelet glycoprotein IIb/IIIa activation by 3,4-methylenedioxy-beta-nitrostyrene, a novel tyrosine kinase inhibitor.
Wang WY; Wu YC; Wu CC
Mol Pharmacol; 2006 Oct; 70(4):1380-9. PubMed ID: 16837624
[TBL] [Abstract][Full Text] [Related]
13. Interaction of human fibrinogen receptor (GPIIb-IIIa) with decorsin.
Yang J; Zhan CY; Dong XC; Yang K; Wang FX
Acta Pharmacol Sin; 2004 Aug; 25(8):1096-104. PubMed ID: 15301746
[TBL] [Abstract][Full Text] [Related]
14. Targeting ligand-induced binding sites on GPIIb/IIIa via single-chain antibody allows effective anticoagulation without bleeding time prolongation.
Stoll P; Bassler N; Hagemeyer CE; Eisenhardt SU; Chen YC; Schmidt R; Schwarz M; Ahrens I; Katagiri Y; Pannen B; Bode C; Peter K
Arterioscler Thromb Vasc Biol; 2007 May; 27(5):1206-12. PubMed ID: 17322097
[TBL] [Abstract][Full Text] [Related]
15. Reversibility versus persistence of GPIIb/IIIa blocker-induced conformational change of GPIIb/IIIa (alphaIIbbeta3, CD41/CD61).
Schwarz M; Katagiri Y; Kotani M; Bassler N; Loeffler C; Bode C; Peter K
J Pharmacol Exp Ther; 2004 Mar; 308(3):1002-11. PubMed ID: 14617694
[TBL] [Abstract][Full Text] [Related]
16. Allicin and disulfiram enhance platelet integrin alphaIIbbeta3-fibrinogen binding.
Manaster Y; Shenkman B; Rosenberg N; Savion N
Thromb Res; 2009 Sep; 124(4):477-82. PubMed ID: 19632706
[TBL] [Abstract][Full Text] [Related]
17. Functional characterization of GPIIb- and GPIIIa-specific monoclonal antibodies. Further evidence for the existence of agonist-specific activated states of the platelet fibrinogen receptor.
de Castellarnau C; Cullaré C; Alvarez MV; Muñiz-Diez E; Calzada MJ; González-Rodríguez J
Platelets; 1997; 8(4):243-53. PubMed ID: 16793655
[TBL] [Abstract][Full Text] [Related]
18. Blockade of glycoprotein IIb/IIIa by crotavirin, a member of disintegrins, prevents platelet from activation and aggregation by Staphylococcus aureus bacteria.
Liu CZ; Huang HY; Tsai PJ; Shih MH
Thromb Res; 2005; 116(2):145-55. PubMed ID: 15907530
[TBL] [Abstract][Full Text] [Related]
19. A mechanistic model for paradoxical platelet activation by ligand-mimetic alphaIIb beta3 (GPIIb/IIIa) antagonists.
Bassler N; Loeffler C; Mangin P; Yuan Y; Schwarz M; Hagemeyer CE; Eisenhardt SU; Ahrens I; Bode C; Jackson SP; Peter K
Arterioscler Thromb Vasc Biol; 2007 Mar; 27(3):e9-15. PubMed ID: 17170374
[TBL] [Abstract][Full Text] [Related]
20. Low molecular weight dual inhibitors of factor Xa and fibrinogen binding to GPIIb/IIIa with highly overlapped pharmacophores.
Trstenjak U; Ilaš J; Kikelj D
Eur J Med Chem; 2013 Jun; 64():302-13. PubMed ID: 23644213
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
